Connect with us

Technology

RLX Technology to Report Second Quarter 2026 Financial Results on August 14, 2026

Published

on

– Earnings Call Scheduled for 8:00 a.m. ET on August 14, 2026 –

SHENZHEN, China, Aug. 5, 2026 /PRNewswire/ — RLX Technology Inc. (“RLX Technology” or the “Company”) (NYSE: RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2026, before the U.S. markets open on Friday, August 14, 2026.

The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 14, 2026 (8:00 PM Beijing/Hong Kong Time on August 14, 2026).

Dial-in details for the earnings conference call are as follows:

United States (toll free):

+1-888-317-6003

International:

+1-412-317-6061

Hong Kong, China:

+852-5808-1995

Mainland China:

400-120-6115

Participant Code (English line):

7036236

Participant Code (Chinese simultaneous interpretation line):

7119184

Participants may choose between the English and Chinese simultaneous interpretation options above when joining the conference call. Please note that the Chinese simultaneous interpretation option is in listen-only mode. Participants should dial-in 10 minutes before the scheduled start time and ask to be connected to the call for “RLX Technology Inc.” using the appropriate English or Chinese Participant Code above.

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.relxtech.com.

A replay of the conference call will be accessible approximately two hours after the conclusion of the call until August 21, 2026, by dialing the following telephone numbers:

United States:

+1-855-669-9658

International:

+1-412-317-0088

Replay Access Code (English line):

9911837

Replay Access Code (Chinese line):

6469534

About RLX Technology Inc.

RLX Technology Inc. (NYSE: RLX) is a leading global branded e-vapor company. The Company leverages its strong in-house technology, and product development capabilities and in-depth insights into adult smokers’ needs to develop superior e-vapor products.

For more information, please visit https://ir.relxtech.com.

View original content:https://www.prnewswire.com/news-releases/rlx-technology-to-report-second-quarter-2026-financial-results-on-august-14-2026-302843615.html

SOURCE RLX Technology Inc.

Continue Reading

Technology

Circular Genomics Advances CircPath™ and Presents Comprehensive Circular RNA Blood Biomarker Data for Early Alzheimer’s Detection and Prediction at CTAD 2026

Published

on

By

Landmark NIH-funded study across nearly 2,400 participants validates circular RNA as a dynamic new molecular intelligence layer, capturing active changes across multiple neurodegenerative pathways years before cognitive decline:

Superior Progression Prediction: Demonstrates a 2.92 Hazard Ratio for predicting symptom onset, 61% stronger than pTau217 alone.Synergistic Performance: Achieves a 4.83 Hazard Ratio for progression and a 0.967 AUC for Alzheimer’s (AD) diagnosis when combined with pTau217, elevating the current standard of care.Crucial Early Window: Detects dynamic molecular divergence before clinical cognitive decline begins.Consistent performance: Delivers consistency for Alzheimer’s disease diagnosis across ancestries.

SAN DIEGO, Nov. 20, 2026 /PRNewswire/ — Circular Genomics, a precision neurology company decoding the dynamic biology of the brain through circular RNA (circRNA) blood biomarkers, today announced the successful presentation of a featured biotech showcase and five comprehensive data posters at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference. Grounded in a landmark NIH-funded study across nearly 2,400 participants, the presented data validates circRNA as a powerful new molecular intelligence layer that predicts Alzheimer’s disease progression years before clinical symptoms emerge.

For over a decade, Alzheimer’s blood diagnostics have relied on measuring single proteins, such as amyloid and tau, which can accumulate silently for decades. Circular Genomics is introducing a fundamentally new category of biomarker. Circular RNAs are highly stable, closed-loop RNA molecules that are enriched in the brain and cross the blood-brain barrier into the bloodstream. Because they reflect active, real-time gene regulation, circRNAs offer a dynamic window into multiple, interconnected brain biological pathways simultaneously, providing researchers with actionable insights into when cognitive symptoms are likely to begin.

Advancing Diagnostics, Prognostics, and Therapeutics 

During the CTAD Biotech Showcase, Nikolaos Mellios, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics, delivered a featured presentation on “Next-Generation circRNA Blood Biomarker Platform for Alzheimer’s Disease Detection, Progression Prediction, and Clinical Deployment”. Dr. Mellios highlighted how the CircPath™ platform, currently available for Research Use Only (RUO), is transforming biopharma clinical trials.

“While amyloid and tau tell us the underlying structural pathology is present, they don’t capture the real-time biological response of the brain,” said Nikolaos Mellios, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics. “By measuring dynamic synaptic, inflammatory, and metabolic changes before symptoms appear, our 34-circRNA signature captures the active and dynamic disease state. When we combine this multi-pathway RNA signal with established markers like pTau217, we achieve a combined hazard ratio over 5. This provides a highly scalable tool to ensure presymptomatic prevention trials are populated with precisely the right patients at the optimal time for intervention; so that, drug developers can drastically improve patient selection and clinical trial efficiencies.”

By delivering whole-transcriptome profiling and targeted prognostic applications, the platform empowers drug developers to de-risk neurological clinical trials. Clinically, this means trial sponsors can now stratify biologically heterogeneous patient cohorts, enrich prevention trials with individuals who are imminently progressing toward cognitive decline, and track multi-pathway pharmacodynamic responses to new therapies from a routine blood draw.

Comprehensive Scientific Evidence Across Poster Presentations 

The five posters presented at CTAD 2026 offered a holistic view of Circular Genomics’ rigorously validated science. Evaluated across three independent cohorts totalling nearly 2,400 individuals, the comprehensive data demonstrated that the company’s proprietary 34-circRNA signature captures dynamic changes in multiple disease pathways providing prognostic information well beyond the identification of Alzheimer’s pathology alone.

Beyond the progression and biological deep dives highlighted below, the posters also confirmed the platform’s exceptional analytical robustness and disease specificity. Research demonstrated that the 34-circRNA signature maintains high specificity for Alzheimer’s disease when measured against non-AD dementias like Parkinson’s disease, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). Furthermore, orthogonal PCR evaluations proved that this blood-based signal can be reliably and consistently measured using quantitative and digital droplet PCR, ensuring the technology is highly scalable for future clinical laboratory deployment.

Highlighted Poster Presentations

Poster P274: Brain-enriched Circular RNAs as Blood-based Biomarkers for Detection of Alzheimer’s Disease-related Biology Across the Disease Continuum

This study examined exactly when circRNA levels shift in relation to clinical disease onset, analyzing a longitudinal cohort of 688 cognitively unimpaired (CU) individuals from the Knight ADRC discovery cohort.

The Science: The 34-circRNA signature detects molecular divergence 4 to 8 years before clinical symptoms emerge, with the most significant shifts occurring 2 to 4 years prior to the onset of cognitive decline.The Outcome: The circRNA model achieved a 0.870 AUC for 5-year progression prediction, drastically outperforming plasma pTau217 (0.676 AUC) and amyloid PET (0.643 AUC). This translates to a notable improvement in predictive accuracy over standard protein tests, giving researchers a crucial early-intervention window to treat patients before irreversible memory loss occurs.

Poster P314: Circular RNA Blood-Based Biomarkers Reliably Predict Progression of Asymptomatic Individuals to Alzheimer’s Disease: ADRC and A4/LEARN Cohort Replication

To validate the reliability of the prognostic signal, Circular Genomics evaluated the fixed 34-circRNA model across two entirely independent, large-scale replication cohorts: a second Knight ADRC cohort (N=551) and the A4/LEARN study (N=318).

The Science: The prediction of progression from cognitively unimpaired to symptomatic Alzheimer’s disease successfully replicated across both cohorts. The model achieved a remarkable 3.83 Hazard Ratio (HR) in the Knight ADRC replication and a 2.93 HR in the A4/LEARN cohort.The Outcome: The data proves that circRNA elevates existing standard-of-care diagnostics performance. When combined with pTau217, the integrated biomarker model pushed the predictive hazard ratio to an unprecedented 5.58 in the Knight ADRC cohort and 4.58 in the A4/LEARN cohort. This synergistic approach drastically reduces cohort heterogeneity, ensuring pharmaceutical sponsors can identify the exact patients most likely to progress during a trial window.

Poster P313: Alzheimer’s Disease Specificity and Consistent Performance of a Circular RNA Blood-Based Biomarker Model Across Diverse Populations This abstract evaluated the 34-circRNA model to ensure it maintains robust performance across diverse genetic ancestries.

The Science: The signature’s performance remains highly consistent across diverse genetic ancestries: including African American, Hispanic, and Asian populations, as well as across sexes and APOE4 genetic statuses.The Outcome: The research confirms that the circRNA signature delivers equitable, highly specific Alzheimer’s disease detection (maintaining an AUC > 0.90 across diverse populations). This ensures broad clinical applicability for underrepresented groups without sacrificing performance driven by genetic ancestry or non-AD dementias.

The robust data presented at CTAD 2026 cements circular RNA as a transformative, complementary layer of molecular intelligence that elevates the current standard of care. While the CircPath™ platform is currently empowering biopharma partners and academic researchers to de-risk clinical trials and track pathway-level disease activity and responses, this comprehensive validation lays the essential groundwork for future clinical diagnostic deployment. By providing a non-invasive window into the brain’s active biology, Circular Genomics is advancing a future where complex neurodegenerative conditions, starting with Alzheimer’s disease and expanding into Parkinson’s disease and ALS, are measurable, manageable, and treatable years before irreversible cognitive decline alters patients’ lives.

About Circular Genomics

Circular Genomics is a precision medicine company developing circular RNA-based diagnostics and therapeutics to transform the understanding and treatment of neuropsychiatric and neurodegenerative conditions. By leveraging novel RNA biology through its proprietary CircPATH™ platform, the company aims to enable earlier detection, more precise patient stratification, and more targeted interventions across brain health. Circular Genomics is headquartered in San Diego, CA. For more information, visit www.circulargenomics.com.

About CircPATH™

CircPATH™ is Circular Genomics’ proprietary end-to-end circular RNA discovery and validation engine, serving as the technological backbone for all of the company’s diagnostic product offerings. The platform systematically identifies disease-relevant circRNAs from complex biological samples, validates their performance across independent cohorts, and translates them into clinically actionable biomarker panels. By leveraging the unique biology of circular RNAs—their stability, tissue specificity, and functional independence from linear transcripts—CircPATH™ unlocks biomarker signals that have remained invisible to conventional approaches. The platform’s ability to discover brain-enriched circRNAs detectable in blood creates a non-invasive window into central nervous system biology, enabling applications across the full spectrum of neurodegenerative and neuropsychiatric conditions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/circular-genomics-advances-circpath-and-presents-comprehensive-circular-rna-blood-biomarker-data-for-early-alzheimers-detection-and-prediction-at-ctad-2026-302944589.html

SOURCE Circular Genomics

Continue Reading

Technology

Headliners Summit Launches Global Leadership Platform in Miami

Published

on

By

Brings together global leaders from government, business, investment, technology, sport and culture to discuss global growth, investment and innovationThe invitation-only convening encourages critical thought that leads to dynamic actionThe annual event will align with the G20 calendar and will take place in London, England in 2027 and Seoul, Korea in 2028

MIAMI, Nov. 20, 2026 /PRNewswire/ — Headliners Summit today announced the speakers at its inaugural edition, Headliners Miami 2026, taking place on December 16 immediately following the G20. The invitation-only global leadership forum will bring together 400 leaders from government, business, investment, technology, sport, and culture and create a platform for critical thinking and dynamic action.

Headliners Summit centers on direct exchanges and meaningful conversation between leaders across a variety of sectors and markets. The single-room format will combine in-depth interviews and focused discussions addressing topics impacting global economies and the era-defining sectors that increasingly intersect. Attendance is only by invitation and application.

Headliners Summit programming examines the connections between capital, artificial intelligence, energy and infrastructure, alongside developments in commercial space, global security, business, sports and culture. Discussions will explore how these fields shape one another, including the power and data infrastructure required for advances in AI.

Speakers include U.S. Secretary of State Marco Rubio; U.S. Secretary of Treasury Scott Bessent; Roger Goodell, Head of the National Football League; Dina Powell McCormick, President of Meta; U.S. Director of National Intelligence Jay Clayton; Greg Brockman, President and Co-Founder of Open AI; Ken Griffin, CEO of Citadel; Antonio Gracias, Founder and CEO, Valor Equity Partners; Craig Robins, Founder and President, Dacra; and several others. On-stage interviews will be conducted by award-winning journalist Bret Baier and the 43rd Mayor of Miami Francis Suarez.

“We are launching Headliners Summit to build an enduring global forum where leaders from across important sectors can engage directly on the decisions shaping the future,” said Francis Suarez and Bret Baier. “From the program of speakers to the audience of decisionmakers, the focus is on pairing critical thinking with dynamic action.”

Headliners Summit is organized around the belief that serious conversations take place when leaders from a cross-section of fields share their expertise and experience with a focused and receptive audience poised to act. The inaugural edition in Miami is the beginning of Headliners Summit’s recurring annual forum connecting leaders and sectors.

About Headliners

Headliners is an invitation-only global leadership forum built around candid conversation and connections across government, capital, technology, energy, infrastructure, space, business and culture. Its inaugural summit will take place in Miami on December 16, 2026, hosted by Francis Suarez, with headline interviews conducted by Bret Baier. For more information, visit www.headlinerssummit.com.

Media Contact:
Headliners Summit
Susan Ainsworth
susan@ainsworthassociates.net
+1-917-861-7949

View original content to download multimedia:https://www.prnewswire.com/news-releases/headliners-summit-launches-global-leadership-platform-in-miami-302946219.html

SOURCE Headliners

Continue Reading

Technology

Golf Legend Annika Sörenstam Talks with Consello’s Declan Kelly About Pushing Past Our Limits

Published

on

By

NEW YORK, Nov. 20, 2026 /PRNewswire/ — In the latest episode of Grey Matter, eight-time LPGA Player of the Year Annika Sörenstam joins Consello Founder, Chairman, and CEO Declan Kelly to discuss how she continued to push past her own limits long after reaching No. 1 in the world.

Sörenstam built, over the course of her professional career, one of the most distinguished records in the history of golf, winning 10 major championships and 72 LPGA Tour events. Even at the height of her success, she remained convinced that she could always improve. In conversation with Kelly, she reflects on why she was never afraid to set ambitious goals, even when she fell short of them, because they helped her discover what she was capable of.

That conviction produced some of the defining moments of her career, including her record round of 59 in 2001, when she set out to birdie every hole, and her decision in 2003 to compete in the PGA Tour’s Colonial. It also governed how Sörenstam prepared, as she recorded every aspect of her game well before the practice became standard. Through that disciplined system of practice, fitness, nutrition, sleep, and mental preparation, she built the foundation for her dominance.

Sörenstam also speaks with candor about the personal side of her career, including overcoming a deep fear of public speaking and her decision to retire from golf while still at the top of the game. The full episode is available at Consello.com and on YouTube, Spotify, and Apple Podcasts.

About Consello

Consello is an Advisory and Investing Platform with offices in New York, Miami, Atlanta, Dublin, Belfast, London, Brussels, and Abu Dhabi.

Consello’s distinct advisory practices provide the complete strategic counsel today’s leaders need to grow and transform their organizations. Consello’s advisory expertise spans Corporate Advisory; M&A; Management Consulting; Talent; and Sports and Entertainment. Dedicated teams operate in each practice, led by a leadership group with deep operational experience across industries, business growth stages and market cycles and with an expansive set of global corporate relationships.

Consello’s investment business, Consello Capital, identifies high-potential mid-market companies and invests capital and expertise to transform their growth.

Consello Media Inquiries
media@consello.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/golf-legend-annika-sorenstam-talks-with-consellos-declan-kelly-about-pushing-past-our-limits-302946294.html

SOURCE Consello

Continue Reading

Trending